In addition, KP104, a bifunctional biologic designed to simultaneously block both the alternative pathway (factor H) and the late complement pathway (C5), is in a phase 2 trial for thrombotic microangiopathies secondary to SLE. This evidence concerns the gene C5 and systemic lupus erythematosus.